Clinical trial
The ASPECT2 Trial: A Phase 3, Randomized, Double-Blind Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
NCT01313572 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The ASPECT2 Trial: A Phase 3, Randomized, Double-Blind Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
- Lead sponsor
- Forest Laboratories
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- August 31, 2011
- Completion date
- April 30, 2012
- Enrollment
- 197 (actual)
- Sites
- 86
Conditions
As the registry lists them; a condition with its own page is linked.